Loss of CHTF18–RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors

Lauryn Buckley-Benbow, Meryem Ozgencil, Alessia Tardocchi, Alessandro Agnarelli, Roberto Bellelli · 2026

Read Loss of CHTF18–RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors by Lauryn Buckley-Benbow, Meryem Ozgencil, Alessia Tardocchi, Alessandro Agnarelli, Roberto Bellelli (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13231162.txt.

Description

Lauryn Buckley-Benbow and colleagues find in 2026 a DNA copying weakness that makes cancer cells extra sensitive to PARP blocking drugs. Those drugs already help tumors with faulty BRCA genes, yet resistance often grows over time. The team removed a clamp-loading complex that helps the main copying enzyme move along the leading DNA strand.

Cells without the complex formed normal repair focus markers, so the classic repair pathway stayed intact. Drug treatment instead piled up small gaps in the newly copied DNA, and trapped drug-bound proteins at those gaps drove the sensitivity. Removing a second repair gene did not rescue the cells, which sets this route apart from BRCA loss. Targeting the copying complex itself may widen the reach of these drugs.

Catalog record

CREATORLauryn Buckley-Benbow, Meryem Ozgencil, Alessia Tardocchi, Alessandro Agnarelli, Roberto Bellelli
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13231162

Browse the full library · About the Tower of Babel